Cancer remains a major public health challenge despite progress in detection and therapy. Mosaiques´ advances in the fields of proteomics provide insights into the molecular complexity of the disease process and thus enable the development of tools to help in treatment as well as in detection and prevention.

We focussed our work on the detection of cancer specific biomarkers in the context of bladder and prostate cancer and cholangiocarcinoma. Biomarkers are biological molecules that are indicators of physiologic state and also of change during a disease process. The utility of a biomarker lies in its ability to provide an early indication of the disease, to monitor disease progression, to provide ease of detection, and to provide a factor measurable across populations for early detection and during therapy.

In contrast to the genome, the proteome is dynamic and is in constant flux because of a combination of factors. These include differential splicing of the respective mRNAs, posttranslational modifications, and temporal and functional regulation of gene expression.